Cost effectiveness of bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) for the first-line treatment of mantle cell lymphoma not eligible for stem cell transplantation: A Scottish perspective

Publication Type:
Conference Proceedings


Citation:

van Keep M, Gairy K, Seshagiri D, Thilakarathne P and Lee D. Cost effectiveness of bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) for the first-line treatment of mantle cell lymphoma not eligible for stem cell transplantation: A Scottish perspective. 18th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Milan, Italy. 7- 11 November 2015. Poster PCN131.

 


Link to publication ⟶

⟵ Back to Search Results